Market News & Trends
Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500 in Combination With Cabozantinib in Clear Cell Renal Carcinoma
Aravive Inc. recently announced positive initial results from the Phase 1b portion of its Phase 1b/2 study in patients dosed with 15 mg/kg of AVB-500…
Genezen Breaks Ground on cGMP Lentiviral Vector Production Facility
Genezen Laboratories, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production, and analytical testing services,…
Schreiner MediPharm & Plas-Tech Engineering Collaborate to Offer Full-Service First-Opening Indication for Prefilled Syringes
Schreiner MediPharm and Plas-Tech Engineering have entered into a collaborative partnership for Cap-Lock – an innovative first-opening indication for prefilled syringes. Schreiner MediPharm initially launched…
Processa Pharmaceuticals Enters Licensing & Development Agreement With Ocuphire Pharma
Processa Pharmaceuticals, Inc. recently announced it has entered into a licensing agreement with Ocuphire Pharma, Inc. to license in RX-3117. RX-3117 is an oral, anticancer…
Onconova Therapeutics Announces Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Rigosertib Combined With Immune Checkpoint Blockade
Onconova Therapeutics, Inc. recently announced the publication of a preclinical study in the journal Molecular Cancer. The study, titled Novel Induction of CD40 Expression by…
BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-Based BNT111 in Patients With Advanced Melanoma
BioNTech SE recently announced the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial (2020-002195-12; NCT04526899). The study is evaluating the…
Nemera Breaks Ground in Brazil Through Milfra Acquisition
Nemera recently announced it has entered into an agreement to acquire Milfra. Milfra, based in Jaguariuna, state of São Paulo, Brazil, specializes in the development…
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study
Biogen Inc. recently announced the first patient has been dosed in the global clinical study, TOPAZ-1. The Phase 3 study will evaluate the clinical efficacy…
LexaGene Detects a Slow-Growing Bacterium at Least 36-Times Faster Than Conventional Methods With Potential to Increase Vaccine Safety & Supply
LexaGene Holdings, Inc. recently announced it has successfully utilized the MiQLab System to detect the presence of a slow growing bacterium, responsible for millions of dollars…
Enterprise Therapeutics Doses First Subjects in Phase 1 Trial for Novel Cystic Fibrosis Therapy
Enterprise Therapeutics Ltd recently announced it has successfully dosed the first subjects in a Phase 1 trial for its novel inhaled cystic fibrosis (CF) therapy,…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….